


Measure	To provide defect free AMI care to all patients	s. Meaning all	of the ACC	/AHA endo	orsed					
Purpose	performance measures are followed for eligit									
Numerator	Count of Care patients that received defect free care for AMI. For the STEMI population:									
	1. Aspirin at Arrival									
	2. Aspirin prescribed at Discharge									
	3. Beta-Blocker Prescribed at Discharge									
	4. Statin Prescribed at Discharge									
	5. Evaluation of LV Systolic Function									
	6. ACEI or ARB for LVSD at Discha	arge								
	7. Time to Fibrinolytic Therapy									
	8. Time to Primary PCI									
	9. Reperfusion Therapy									
	10. Adult Smoking Cessation Advice	0								
	11. Cardiac Rehabilitation Patient Ref	erral From ar	1							
	Inpatient Setting	Inpatient Setting								
	For the NSTEMI population:									
	1. Aspirin at Arrival									
	2. Aspirin prescribed at Discharge									
	3. Beta-Blocker Prescribed at Discharge									
	4. Statin Prescribed at Discharge	C								
	5. Evaluation of LV Systolic Function									
	6. ACEI or ARB for LVSD at Discharge									
	7. Adult Smoking Cessation Advice Counseling									
	8. Cardiac Rehabilitation Patient Referral From an									
_	Inpatient Setting									
Denominator	Count of patients that had an acute myocardia		.1 1.	• 1 1	.1					
Exclusions	Patients must be eligible for care. If the patient the patient is not eligible for care.			ndual mea	sure then					
Demonstrated Opportunity	Exclusions	Number of Sta	ay		r of Facilities					
for Improvement		#	%	#	%					
·F	Initial Sample	483534	100	839	100					
	Discharges not between Jan 2011 and Dec 2012	211937	43.83	91	10.85					
	Remaining	271597	56.17	748	89.15					
	Age<18	0	0.00	0	0.00					
	Remaining	271597	100.00	748	100.00					
	Hospital submission that did not pass the data			100						
	quality check	53561	19.72	190	25.40					
	Remaining	218036	80.28	558	74.60					
	Not eligible to the defect free care measure Study Sample	10510 207526	4.82	0 558	0.00					
	The defect free care measure	140762	95.18 67.83	558	100.00 99.10					
		140702	07.05	555	77.10					

Name			E	Denomina	ntor	Numerator	Rate
Appirin of Arrival				1200.42		100500	00.11
Aspirin at Arrival			130943		128532	98.16	
Aspirin prescribed at Di			175010		171970	98.26	
Beta-Blocker Prescribe			183659		177918	96.87	
Statin Prescribed at Dis				179373		176651	98.48
Evaluation of LV Systol				193716		183693	94.83
ACEI or ARB for LVSD				31669		28208	89.07
Time to Fibrinolytic The		inutes		255		117	45.88
Time to Balloon: <90 m	inutes			44770		42332	94.55
Reperfusion Therapy	• • • •			75042		65730	87.59
Adult Smoking Cessatio				69478		68341	98.36
Cardiac Rehabilitation F Inpatient Setting	atient Refe	rral From	an	179445	;	138660	77.27
			I		I		I
Т	able 1 Select	ed Chara	cteristics	by Calen	dar Year		
	То	Total		Year			
Description	_	1		2011		012	Р
	#	%	#	%	#	%	
				ļ			
ALL		100.0		100.0		100.0	
	207526	0	93977	0	113549	0	
Age>=65							0.0009
No	109557	52.79	49989	53.19	59568	52.46	
Yes	97969	47.21	43988	46.81	53981	47.54	
Female							0.7812
No	135678	65.38	61471	65.41	74207	65.35	
Yes	71848	34.62	32506	34.59	39342	34.65	
RACE							0.0000
White non-Hispanic	10604	5.11	4562	4.85	6042	5.32	
Black non-Hispanic	167928	80.92	76480	81.38	91448	80.54	
Hispanic	23595	11.37	10606	11.29	12989	11.44	
Other	5399	2.60	2329	2.48	3070	2.70	
Random Splitting							
Samples							0.1104
First	103848	50.04	47208	50.23	56640	49.88	
	103678	49.96	46769	49.77	56909	50.12	
Second	100070		1	1	1	1	
Second Safety Net Hospital*	100070						0.0000
	920	0.44	436	0.46	484	0.43	0.0000
Safety Net Hospital*		0.44 82.64	436 77050	0.46 81.99	484 94451	0.43 83.18	0.0000

	Hospital % Non-White							0.0000
	Q1	43863	21.14	20066	21.35	23797	20.96	
	Q2	55172	26.59	24423	25.99	30749	27.08	
	Q3	58284	28.09	26591	28.30	31693	27.91	
	Q4	50207	24.19	22897	24.36	27310	24.05	
	Hospital % Medicaid*							0.0000
	Unknown	920	0.44	436	0.46	484	0.43	
	Q1	48240	23.25	21771	23.17	26469	23.31	
	Q2	54076	26.06	25126	26.74	28950	25.50	
	Q3	53172	25.62	22908	24.38	30264	26.65	
	Q4	51118	24.63	23736	25.26	27382	24.11	
	The Composite Measure							0.0000
	Performance Not Met	66764	32.17	31098	33.09	35666	31.41	
	Performance Met	140762	67.83	62879	66.91	77883	68.59	
	* Hospital information about 2010 data.	it the SNH a	and %Med	licaid are d	erived fro	om AHA		
	1				arge Str	atified by		et Status
	2010 data.				arge Str		Status	
	2010 data.				arge Str	atified by	Status	et Status ′es
	2010 data.				arge Str	atified by	Status Y	
	2010 data. Distribution of The Control Description				arge Str S No	atified by	Status Y	′es
	2010 data. Distribution of The Control Description N				arge Str S No 1153	atified by	Status Υ 2 0.8	'es
	2010 data. Distribution of The Control Description N Mean				arge Str S No 1153 0.8732	atified by	Status Y 2 0.8 0.1	' es 13 3537
	2010 data. Distribution of The Co Description N Mean Std Deviation				arge Str S No 1153 0.8732 0.0851	atified by	Status Y 2 0.8 0.1	'es 13 3537 1004
eliability esting	2010 data. Distribution of The Co Description N Mean Std Deviation 75% Q3				arge Str S No 1153 0.8732 0.0851 0.9333	atified by	Status Y 2 0.8 0.1 0.2 0.2 0.2	Yes 13 3537 1004 9296









llse ofthe composite measure at Discharge (%)				
lse of the o		•	•	
Distribut	ion of The C	omposite Measure at Dis	scharge Stratified by Ra	
	ion of The C	omposite Measure at Dis		
	ion of The C Hispanic			ace Othe
Distribut Description		Rac	e	
Description	Hispanic	Rac White non-Hispanic	e Black non-Hispanic	Othe
Description N Mean	Hispanic 1317	Rac White non-Hispanic 1386	e Black non-Hispanic 1304	Othe 1274 0.885
Description N Mean Std Deviation	Hispanic 1317 0.8783 0.1666	Rac White non-Hispanic 1386 0.8688 0.0900	e Black non-Hispanic 1304 0.8726 0.1432	Othe 1274 0.885 3 0.160 7 1.000
Description N Mean	Hispanic 1317 0.8783	Rac White non-Hispanic 1386 0.8688	e Black non-Hispanic 1304 0.8726	Othe 1274 0.885 3 0.160 7

	<u>ę</u> .	-				
	je Geo					
	Use of the composite measure at Discharge (%) 20 40 60 80					
	freat 60					
	leasu					
	site⊤ 40 ·				:	
	öd Щ	•			:	
	20 the cc	:		•	•	
	e oft	Ť		·	•	
	0.	1 •			· ·	
		hispanio	c white	non-hispanic	black non-his	panic
Distribution o		Composi		re at Disc		-
	k	Composi by Hospi	te Measu	re at Disc icaid*	charge St	-
Distribution o	k	Composi	te Measu	re at Disc icaid*		-
	k	Composi by Hospi	te Measu tal %Med	re at Disc icaid* %Mee	charge St	ratified
	8 %M	Composi by Hospi	te Measu tal %Med	re at Disc icaid* %Mee	charge St	ratified
Description N Mean	%M	Composi by Hospit ledicaid 1366 18.39	te Measu tal %Med Q1 341 0.8782	re at Disc icaid* %Mee Q2 342 0.8681	charge St dicaid Q3 342 0.8715	Q4 341 0.8629
Description	%M	Composi by Hospi ledicaid	te Measu tal %Med Q1 341	re at Disc icaid* %Me Q2 342	harge St dicaid Q3 342	Q4
Description N Mean Std Deviation	%M	Composi by Hospit ledicaid 1366 18.39 8.82	te Measu tal %Med Q1 341 0.8782 0.0786	re at Disc icaid* %Mee Q2 342 0.8681 0.0795	charge St dicaid Q3 342 0.8715 0.0945	Q4 341 0.8629 0.0971
Description N Mean	1 %M	Composi by Hospit ledicaid 1366 18.39	te Measu tal %Med Q1 341 0.8782	re at Disc icaid* %Mee Q2 342 0.8681	charge St dicaid Q3 342 0.8715	Q4 341 0.8629





Page 10 of 13

	6270	Beta Blocker at Discharge	0.824	0.761 - 0.887	4	94.0%
	6320	ACE Inhibitor at Discharge	0.811	0.758 - 0.864	4	89.0%
	6470	Statin at Discharge	0.843	0.782 - 0.904	4	94.3%
	7011	LVEF Not Assessed	0.602	0.469 - 0.736	2	93.0%
	7100	PCI	0.987	0.97 - 1	2	99.3%
	8000	Reperfusion Candidate	0.606	0.534 - 0.678	3	80.7%
	8020	Thrombolytics	0.669	0.592 - 0.746	3	85.3%
	1110 0	Discharge Status	0.934	0.844 - 1	2	99.7%
	1110 1	Smoking Counseling	0.756	0.688 - 0.823	3	89.7%
	1110 4	Cardiac Rehabilitation Referral	0.386	0.314 - 0.458	4	65.3%
	1110 5	Discharge Location	0.808	0.746 - 0.87	8	91.7%
Testing	Content v individua group con identifyir experts in eligible p NCDR Sci resource members Reynolds Tcheng, NCDR Str that serve methodo registries outcome NCDR AR the meas there is c measure. These me Robert L. Michael C Harold L. F.A.C.C.	<u>ic assessment of content validity</u> : validity of this process was achieved is who developed this measure as inducted. For this particular topic this is the key attributes and variables is opulation and given process. These entific Quality and Oversight Comm for crosscutting scientific and qual included Drs. Frederick Masoudi (is, David Shahian, John Windle, Free Jeptha Curtis, Paul Chan, Matthew rategic Quality and Oversight Comm es as the primary resource for cros logical issues – ensured the data di s. They also reviewed and approved and model. E-G Steering Committee provides st ures submitted to NQF met key crit ompelling evidence base behind th embers include James G. Jollis, M.D., McNamara, M.D., M.H.S., F.A.C.C., Iw C. Kontos, M.D., F.A.C.C., Steven V. M Dauerman, M.D., F.A.C.C., Martha J. ang, M.D., F.A.C.C.	well as th nose indiv for this pr rial phone e clinical le nittee—a ity of care (Chair), D d Resnic, Roe, and nittee— a scutting s ctionaries I the meth rategic dif erion suc e develop , F.A.C.C., I van Rokos anoukian	e structured di iduals who we ocess measure e calls were hele eaders are note committee tha e methodologic avid Malenka, ' John Moore, D John Rumsfeld n ACC leadersh cientific and qu and metrics an odology and re rection for the h as reliability, ment and impl Deepak L. Bhat c, M.D., F.A.C.C., , M.D., F.A.C.C.,	scussion re involv were lea d to both ed below t served al issues Thomas ' eepak Bl ip overs ality of o re consis esults of Registry feasibili ementat t, M.D., M Michael Harper S	s that the ed in aders and define the as the primary . These Tsai, Matthew natt, James ight committee care tent across the bleeding and ensures ty, and that ion of this I.P.H., F.A.C.C., A. Ross, M.D., Stone, MD,

Confounding Bias: No empirical testing was performed since this metric is neither an outcome or resource use measure.

Evidence:

Many references are noted below including guidelines, focued updates to guidelines and performance measures endorsed by the American College of Cardiology and American Heart Association.

Krumholz HM, Anderson JL, Bachelder BL, Fesmire FM, Fihn SD, Foody JM, Ho PM, Kosiborod MN, Masoudi FM, Nallamothu BK. ACC/AHA 2008 performance measures for adults with STelevation and non–ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non–ST-Elevation Myocardial Infarction). J Am Coll Cardiol 2008;52:2046–99.

Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons, endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50:e1–157.

Antman EM, Hand M, Armstrong PW, et al. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2008;51:210–47.

Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). J Am Coll Cardiol. 2004;44:E1–211.

Antman EM, Hand M, Armstrong PW, et al. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of

Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2008;51:210–47.

Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions,

and the Society of Thoracic Surgeons, endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50:e1–157.